Treceți offline cu aplicația Player FM !
Podcasturi care merită ascultate
SPONSORIZAT
![We Have The Receipts podcast artwork](https://cdn.player.fm/images/37350108/series/3hptiqPGSZRELxyS/32.jpg 32w, https://cdn.player.fm/images/37350108/series/3hptiqPGSZRELxyS/64.jpg 64w, https://cdn.player.fm/images/37350108/series/3hptiqPGSZRELxyS/128.jpg 128w, https://cdn.player.fm/images/37350108/series/3hptiqPGSZRELxyS/256.jpg 256w, https://cdn.player.fm/images/37350108/series/3hptiqPGSZRELxyS/512.jpg 512w)
![We Have The Receipts podcast artwork](/static/images/64pixel.png)
1 Love Is Blind S8: Pods & Sober High Thoughts with Courtney Revolution & Meg 1:06:00
02_07 HER-2 positive breast cancer: Considerations in advanced disease
Manage episode 352932938 series 3335024
1. Anti-HER2 agent classes
2. Cleopatra Trial
3. Later line options
4. Leptomeningeal carcinomatosis
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode:
1. Dawood S et al. NEJM. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101
3. Baselga J et al. NEJM. 2012;366(2):109-119. doi:10.1056/NEJMOA1113216/
4. Swain SM et al. NEJM. 2015;372(8):724-734. doi:10.1056/NEJMOA1413513/
5. Verma S et al. T. NEJM. 2012;367(19):1783-1791. doi:10.1056/NEJMOA1209124/
6. Cortés J et al. NEJM. 2022;386(12):1143-1154. doi:10.1056/NEJMOA2115022/
7. Krop IE et al. Lancet Oncol. 2017;18(6):743-754. doi:10.1016/S1470-2045(17)30313-3
8. Murthy RK et al. NEJM. 2020;382(7):597-609. doi:10.1056/NEJMOA1914609/
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
49 episoade
02_07 HER-2 positive breast cancer: Considerations in advanced disease
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
Manage episode 352932938 series 3335024
1. Anti-HER2 agent classes
2. Cleopatra Trial
3. Later line options
4. Leptomeningeal carcinomatosis
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode:
1. Dawood S et al. NEJM. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101
3. Baselga J et al. NEJM. 2012;366(2):109-119. doi:10.1056/NEJMOA1113216/
4. Swain SM et al. NEJM. 2015;372(8):724-734. doi:10.1056/NEJMOA1413513/
5. Verma S et al. T. NEJM. 2012;367(19):1783-1791. doi:10.1056/NEJMOA1209124/
6. Cortés J et al. NEJM. 2022;386(12):1143-1154. doi:10.1056/NEJMOA2115022/
7. Krop IE et al. Lancet Oncol. 2017;18(6):743-754. doi:10.1016/S1470-2045(17)30313-3
8. Murthy RK et al. NEJM. 2020;382(7):597-609. doi:10.1056/NEJMOA1914609/
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
49 episoade
Tous les épisodes
×![Artwork](/static/images/128pixel.png)
1 05_01 Hepatocellular carcinoma 32:13
![Artwork](/static/images/128pixel.png)
1 04_08 Metastatic Renal Cell Carcinoma 24:16
![Artwork](/static/images/128pixel.png)
1 04_07 Localized Renal Cell Carcinoma 25:15
![Artwork](/static/images/128pixel.png)
1 04_06 Metastatic Urothelial Cancer 24:33
![Artwork](/static/images/128pixel.png)
1 04_05 Muscle Invasive Bladder Cancer 29:16
![Artwork](/static/images/128pixel.png)
1 01_14 Ampullary Carcinoma (Mini Discussion) 10:59
![Artwork](/static/images/128pixel.png)
1 04_04 Castrate Resistant Metastatic Prostate Cancer 24:50
![Artwork](/static/images/128pixel.png)
1 04_03 Metastatic Castrate Sensitive Prostate Cancer 29:02
![Artwork](/static/images/128pixel.png)
1 04_02 Adjuvant Options for Prostate Cancer 28:41
![Artwork](/static/images/128pixel.png)
1 04_01 Fundamentals of Localized Prostate Cancer 31:59
![Artwork](/static/images/128pixel.png)
1 03_13 Head and Neck Cancer – Locally advanced and metastatic 37:18
![Artwork](/static/images/128pixel.png)
1 03_12 Head and Neck Cancer – Background and adjuvant considerations 23:28
![Artwork](/static/images/128pixel.png)
1 03_11 Mesothelioma and a bit of Large Cell Neuroendocrine Carcinoma 29:40
Bun venit la Player FM!
Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.